Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Marinus (MRNS – Research Report) today and set a price target of $17.00. The company’s shares closed last Thursday at $5.02, close to its 52-week low of $4.19.
According to TipRanks.com, Higgins is a 2-star analyst with an average return of 0.8% and a 28.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Armata Pharmaceuticals.
Currently, the analyst consensus on Marinus is a Strong Buy with an average price target of $29.50, a 431.5% upside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $32.00 price target.
Marinus’ market cap is currently $186.4M and has a P/E ratio of -2.03.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
Read More on MRNS:
- Analysts Conflicted on These Technology Names: MongoDB (MDB) and DocuSign (DOCU)
- Bank of America Securities Keeps a Buy Rating on Alibaba (BABA)
- Resmed (RMD) Receives a Hold from Needham
- Bank of America Securities Reiterates Their Buy Rating on NextEra Energy (NEE)
- Analysts Offer Insights on Technology Companies: Advanced Micro Devices (AMD) and Rigetti Computing (RGTI)